Bizengri Receives FDA National Priority Nod for Rare Bile Duct Cancer
Decision brief
Answer first · skim in under a minute
Bizengri, a bispecific drug, has received FDA's national priority designation for treating rare bile duct cancer. This approval could reshape the competitive landscape in oncology.
Bizengri received an FDA approval on May 8, 2026 for rare NRG1 fusion-positive bile duct cancer, not a vague future designation. Partner Therapeutics' zenocutuzumab-zbco cleared under the Commissioner's National Priority Review Voucher pilot with measurable eNRGy trial results.
Contents9 sections
Key Takeaways
- FDA approved Bizengri (zenocutuzumab-zbco) on May 8, 2026 for adults with advanced unresectable or metastatic cholangiocarcinoma harboring an NRG1 gene fusion after prior systemic therapy.
- The application used the Commissioner's National Priority Review Voucher (CNPV) pilot and finished more than five months ahead of the FDA goal date.
- In eNRGy (NCT02912949), confirmed ORR was 36.8% (95% CI: 16.3, 61.6) among 19 efficacy-evaluable NRG1 fusion-positive cholangiocarcinoma patients.
- Duration of response ranged from 2.8 to 12.9 months by blinded independent central review using RECIST v1.1.
What exactly did FDA approve for Bizengri?
On May 8, 2026, the Food and Drug Administration approved zenocutuzumab-zbco (Bizengri, Partner Therapeutics, Inc.) for adults with advanced, unresectable or metastatic cholangiocarcinoma harboring a neuregulin 1 (NRG1) gene fusion with disease progression on or after prior systemic therapy.
FDA's approval notice calls NRG1-fusion positive cholangiocarcinoma an extremely rare, life-threatening malignancy. That framing matters for BD teams: the commercial pool is biomarker-defined and small, so testing access drives uptake as much as list price.
Older secondary writeups that described Bizengri as still seeking a priority tag after an October date were wrong against the FDA record and should not be used in diligence.
How does the CNPV pilot change the review story?
FDA said the Bizengri application is part of the Commissioner's National Priority Review Voucher pilot, designed to accelerate products that address key national priorities.
The same notice states FDA approved the application more than five months ahead of the goal date, used the Assessment Aid, and granted priority review. Zenocutuzumab-zbco also carried breakthrough designation and orphan drug designation under FDA expedited programs.
For competitive intelligence, the practical signal is calendar compression: a rare-disease bispecific reached a dated label faster than a standard priority clock would imply.
What did the eNRGy trial show?
Safety and efficacy came from eNRGy (NCT02912949), a multicenter, open-label, multi-cohort trial in adults with advanced solid tumors.
FDA reported that 22 patients with unresectable or metastatic NRG1 fusion-positive cholangiocarcinoma enrolled, with 19 evaluable for efficacy. Major endpoints were confirmed overall response rate and duration of response by blinded independent central review per RECIST v1.1.
ORR was 36.8% (95% CI: 16.3, 61.6). Duration of response ranged from 2.8 to 12.9 months. The prescribing information includes warnings for infusion-related reactions and hypersensitivity, among other precautions listed on the FDA page.
Why does NRG1 fusion testing decide commercial value?
Bizengri's label is limited to NRG1 fusion-positive disease after prior systemic therapy. Without routine fusion testing in cholangiocarcinoma workups, eligible patients will be missed even if the drug is stocked.
Investors should therefore track companion testing pathways, turnaround time at major GI oncology centers, and whether pathology groups add NRG1 fusion assays to standard panels. Those operational metrics will move share faster than broad bile-duct cancer incidence slides.
Place the approval beside other May 2026 oncology actions summarized in NovaPharma's May 2026 FDA drug approvals regulatory roundup.
What should BD and investor teams watch next?
Watch label uptake in NRG1-positive referrals, not total cholangiocarcinoma volume. Watch whether Partner Therapeutics partners U.S. commercialization or keeps field force control. Watch manufacturing scale for a bispecific serving a rare fusion niche.
Also compare sequencing with other targeted GI oncology assets covered in NovaPharma's manufacturing and approvals evidence brief and pipeline catalyst notes such as Sanofi's 2026 catalysts overview.
Discard any diligence memo that cites a seventh priority tag on an October date without an FDA primary URL. The controlling facts are May 8, 2026 approval, CNPV timing, and eNRGy ORR 36.8%.
Related NovaPharma coverage
- May 2026 FDA drug approvals regulatory roundup
- Manufacturing pipeline approvals: what the evidence confirms
- FDA approves Vertex Journavx for acute pain
Frequently Asked Questions
When did FDA approve Bizengri for cholangiocarcinoma?
On May 8, 2026, FDA approved zenocutuzumab-zbco (Bizengri, Partner Therapeutics) for adults with advanced, unresectable or metastatic NRG1 fusion-positive cholangiocarcinoma after prior systemic therapy.
What response rate did Bizengri show in eNRGy?
In 19 efficacy-evaluable patients with NRG1 fusion-positive cholangiocarcinoma in eNRGy (NCT02912949), confirmed overall response rate was 36.8% (95% CI: 16.3, 61.6), with duration of response from 2.8 to 12.9 months.
What is the CNPV pilot for Bizengri?
FDA said the Bizengri application was part of the Commissioner's National Priority Review Voucher pilot and finished more than five months ahead of the agency goal date, with priority review, breakthrough designation, and orphan drug designation.
Primary Sources
Regulatory catalyst tracker
Track PDUFA dates, approval milestones, and label updates for Bizengri.
Unlock full calendar →Investor brief
Download a one-page summary of regulatory impact and competitive context.
Explore drug hub →Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
